Day: October 23, 2020

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients

The following is an excerpt from a statement from Octapharma. Read the statement in its entirety here. LACHEN, Switzerland- Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). NUWIQ ®Â is approved for the prevention and treatment of bleeding […]